Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols.
BACKGROUND
The clinical utility for mefloquine has been eroded due to its association with adverse neurological effects. Better-tolerated alternatives are required. The objective of the present study was the identification of lead compounds that are as effective as mefloquine, but exhibit physiochemical properties likely to render them less susceptible to passage across the blood-brain barrier.


METHODS
A library of drug-like non-piperidine analogs of mefloquine was synthesized. These compounds are diverse in structure and physiochemical properties. They were screened in appropriate in vitro assays and evaluated in terms of their potential as lead compounds. The correlation of specific structural attributes and physiochemical properties with activity was assessed.


RESULTS
The most potent analogs were low molecular weight unconjugated secondary amines with no heteroatoms in their side-chains. However, these compounds were more metabolically labile and permeable than mefloquine. In terms of physiochemical properties, lower polar surface area, lower molecular weight, more freely rotatable bonds and fewer H-bond acceptors were associated with greater potency. There was no such relationship between activity and LogP, LogD or the number of hydrogen bond donors (HBDs). The addition of an H-bond donor to the side-chain yielded a series of active diamines, which were as metabolically stable as mefloquine but showed reduced permeability.


CONCLUSIONS
A drug-like library of non-piperidine analogs of mefloquine was synthesized. From amongst this library an active lead series of less permeable, but metabolically stable, diamines was identified.
Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, USA. erin.milner@amedd.army.mil
Erin
E
Milner
William
W
McCalmont
Jayendra
J
Bhonsle
Diana
D
Caridha
Jose
J
Cobar
Sean
S
Gardner
Lucia
L
Gerena
Duane
D
Goodine
Charlotte
C
Lanteri
Victor
V
Melendez
Norma
N
Roncal
Jason
J
Sousa
Peter
P
Wipf
Geoffrey Stuart
GS
Dow
D000962:Antimalarials / Q000493:pharmacokinetics / Q000494:pharmacology*; D055808:Drug Discovery; D019271:Hypoxanthine; D015767:Mefloquine / Q000494:pharmacology / Q000633:toxicity; D000432:Methanol / Q000493:pharmacokinetics / Q000494:pharmacology*; D010539:Permeability; D010963:Plasmodium falciparum / Q000187:drug effects*; D011804:Quinolines / Q000493:pharmacokinetics / Q000494:pharmacology*
D000962:Antimalarials; D011804:Quinolines; D019271:Hypoxanthine; C037219:quinoline; D015767:Mefloquine; D000432:Methanol